25.08.2019 20:00:00

Better Buy: Biogen vs. Celgene

Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) claimed similar market caps earlier this year. That's not the case now, though. In March, Biogen announced that it was halting late-stage clinical studies for its once-promising Alzheimer's disease drug, aducanumab. The biotech's shares collapsed. Celgene's market cap now stands well above Biogen's.But with Celgene months away from being gobbled up by Bristol-Myers Squibb (NYSE: BMY) and Biogen's valuation taking a shellacking, which of these two biotech stocks is the better pick for investors now? Here's how the companies compare in three key areas.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Biogen Inc Unsponsored Brazilian Depository Receipt Repr 1-6 Shsmehr Analysen

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!

Aktien in diesem Artikel

pagehit